Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 8/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652178 | 0.92 | HTR4 (0.39) | KDM4EHTR4CYP3A4CYP2D6POLB | |
| SCHEMBL19652172 | 0.87 | ACHE (0.40) | HTR4DPP4PREPFAP | |
| SCHEMBL19658488 | 0.87 | ACHE (0.44) | HTR4DPP4PREPFAP | |
| SCHEMBL14540448 | 0.87 | KDM4E (0.44) | KDM4EPOLBKMT2ADPP4PREP | |
| SCHEMBL19652209 | 0.86 | ACHE (0.46) | HTR4DPP4PREPFAP | |
| SCHEMBL19658599 | 0.85 | KDM4E (0.40) | KDM4EHTR4CYP3A4CYP2D6THRB | |
| SCHEMBL19652262 | 0.80 | SMN1; SMN2 (0.42) | KDM4EDPP4PREPFAP | |
| SCHEMBL19652176 | 0.80 | CHRM4 (0.37) | KDM4EKMT2ADPP4PREPFAP | |
| SCHEMBL22856554 | 0.79 | PIK3CD (0.41) | KDM4ECYP2D6DPP4PREPFAP | |
| SCHEMBL26145707 | 0.78 | KDM4E (0.38) | KDM4EPOLBKMT2ADPP4PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | KDM4E 320/4885HTR4 3406/4885CYP3A4 4473/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | KDM4E 320/4885HTR4 3406/4885CYP3A4 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.